Rona Therapeutics Inc., a global leader in RNA-targeted therapeutics, announced the clearance of an Investigational New Drug (IND) by the U.S. Food and Drug Administration (FDA) forRN0361-an ...

Drug developers' dreams of silencing RNA as a way to step in front of a range of diseases have not lived up to early-day hype ...

Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

The authors state that they have obtained appropriate institutional review board approval or have followed ... (carrier), doxorubicin (anticancer drug), siRNA targeted to mRNA-encoding proteins ...

“Once you have figured out how to design an siRNA and deliver it ... system’ has already been used to create six FDA-approved drugs – five of them discovered by Alnylam.

Eli Lilly has teamed up with insitro to develop treatments for metabolic diseases, combining insitro’s artificial intelligence (AI) machine learning (ML) platform with Lilly’s drug delivery ...

Multidrug-resistant bacteria pose a major threat to human health. Manipulation of bacterial genes at the transcriptional level is a potential strategy to fight antibiotic-resistant bacterial ...

Each siRNA is a complementary sequence to a key ... forward for delivery to other tissue types. The first three approved RNAi drugs — all discovered and developed at Alnylam — were for rare ...

Leqvio belongs to a group of drugs called small interfering RNA (siRNA). This article describes ... No, Leqvio has not been approved by the Food and Drug Administration (FDA) for use in children.

Prof. Dr. Olivia Merkel, Professor of Drug Delivery, explained: “Nanoencapsulation is a highly efficient way to deliver siRNA to targets across the cellular membrane, protecting it from degradation ...